{
    "nctId": "NCT04246502",
    "briefTitle": "Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer",
    "officialTitle": "A Phase 2,Randomized, Evaluate Efficacy and Safety of Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2 positive recurrent or metastasis breast cancer.\n* Patients with measurable disease are eligible.\n* Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.\n* Adequate organ function.\n* Signed, written inform consent obtained prior to any study procedure.\n\nExclusion Criteria:\n\n* History of anti-cancer therapy for MBC\uff08with the exception of one prior hormonal regimen for MBC\uff09.\n* History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in any treatment setting\uff0cexcept trastuzumab used in the neo-adjuvant or adjuvant setting.\n* Assessed by the investigator to be unable receive systemic chemotherapy.\n* History of other malignancy within the last 5 years\uff0cexcept for carcinoma in situ of cervix\uff0cbasal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.\n* Pregnant or lactating women\uff0cor for women of childbearing potential unwilling to use a highly-effective contraception during of the study treatment and for at least 7 months after the last dose of study treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}